UCB (OTCMKTS:UCBJY) Share Price Passes Above 50-Day Moving Average - Should You Sell?

Key Points

• UCB SA's stock price recently crossed above its 50-day moving average of $94.84, reaching a high of $107.38 before last trading at $105.02.
• Goldman Sachs upgraded UCB to a "strong-buy" rating, indicating positive outlook among analysts.
• The company's debt-to-equity ratio is 0.30, suggesting relatively low financial risk compared to other companies in the sector.

UCB SA (OTCMKTS:UCBJY - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $94.84 and traded as high as $107.38. UCB shares last traded at $105.02, with a volume of 44,013 shares traded.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group upgraded UCB to a "strong-buy" rating in a research note on Wednesday, July 16th.

UCB Stock Down 0.3%

The stock's 50 day moving average is $94.84 and its two-hundred day moving average is $93.26. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.99 and a current ratio of 1.36.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.